| Bioactivity | Evifacotrep, a short transient receptor potential channel 5 (TRPC5) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases[1]. | ||||||||||||
| Target | TRPC5 | ||||||||||||
| Invitro | Evifacotrep is a short transient receptor potential channel 5 (TRPC5) antagonist[1]. | ||||||||||||
| Name | Evifacotrep | ||||||||||||
| CAS | 2413739-88-3 | ||||||||||||
| Formula | C18H12ClF4N5O2 | ||||||||||||
| Molar Mass | 441.77 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. WO2020061162 |
Evifacotrep
CAS: 2413739-88-3 F: C18H12ClF4N5O2 W: 441.77
Evifacotrep, a short transient receptor potential channel 5 (TRPC5) antagonist (WO2020061162, compound 100), can be used
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.